Características da Precipitação em Área de Floresta Primária e Área de Pastagem no Estado de Rondônia

Este estudo analisa os totais mensais e a distribuição horária daprecipitação na Reserva Biológica do Jaru (REBIO Jaru) e na Fazenda NossaSenhora (FNS) no ano de 1999 a 2006, ambas localizadas no Estado deRondônia. O resultado dessas análises mostra que a REBIO Jaru apresentouprecipitação 20%, em média, superior a FNS, e ambos os sítios apresentaramuma maior incidência de chuvas no final do dia, onde a FNS tempico em média às 18h e a REBIO Jaru às 17h

Effects of land‐cover changes on the partitioning of surface energy and water fluxes in Amazonia using high‐resolution satellite imagery

Spatial variability of surface energy and water fluxes at local scales is strongly controlled by soil and micrometeorological conditions. Thus, the accurate estimation of these fluxes from space at high spatial resolution has the potential to improve prediction of the impact of land‐use changes on the local environment. In this study, Advanced Spaceborne Thermal Emission and Reflection Radiometer (ASTER) and Large‐Scale Biosphere‐Atmosphere Experiment in Amazonia (LBA) data were used to examine the partitioning of surface energy and water fluxes over different land‐cover types in one wet year (2004) and one drought year (2005) in eastern Rondonia state, Brazil. The spatial variation of albedo, net radiation (Rn), soil (G) and sensible (H) heat fluxes, evapotranspiration (ET), and evaporative fraction (EF) were primarily related to the lower presence of forest (primary [PF] or secondary [SF]) in the western side of the Ji‐Parana River in comparison with the eastern side, located within the Jaru Biological Reserve protected area. Water limitation in this part of Amazonia tends to affect anthropic (pasture [PA] and agriculture [AG]) ecosystems more than the natural land covers (PF and SF). We found statistically significant differences on the surface fluxes prior to and ~1 year after the deforestation. Rn over forested areas is ~10% greater in comparison with PA and AG. Deforestation and consequent transition to PA or AG increased the total energy (~200–400%) used to heat the soil subsurface and raise air temperatures. These differences in energy partitioning contributed to approximately three times higher ET over forested areas in comparison with nonforested areas. The conversion of PF to AG is likely to have a higher impact in the local climate in this part of Amazonia when compared with the change to PA and SF, respectively. These results illustrate the importance of conserving secondary forest areas in Amazonia.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151879/1/eco2126_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/151879/2/eco2126.pd

ECOSSISTEMA DE INOVAÇÃO PEDAGÓGICA DIGITAL

Resumo: A partir da constatação de que os elementos vida, conhecimento e cultura vem sofrendo marcantes alterações cabendo ao elemento “escola” buscar uma ressignificação de seus currículos, sob pena de não mais se comunicar eficientemente com a sociedade. O professor que se reconhece como o protagonista de sua prática e utiliza as tecnologias educacionais de modo crítico e criativo, coloca-se em sintonia com as linguagens e símbolos que fazem parte deste novo mundo do aluno, além de conferir a este maior autonomia e reponsabilidade sob seu processo de aprendizagem. O objetivo geral deste projeto foi de estruturar um conjunto de ações que despertassem e capacitassem professores e alunos a atuarem mediados por tecnologias educacionais de modo crítico e criativo, colocando-os em sintonia com as linguagens e símbolos que fazem parte deste novo mundo digital e interconectado

Photography-based taxonomy is inadequate, unnecessary, and potentially harmful for biological sciences

The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007; Donegan 2008, 2009; Nemésio 2009a–b; Dubois 2009; Gentile & Snell 2009; Minelli 2009; Cianferoni & Bartolozzi 2016; Amorim et al. 2016). This question was again raised in a letter supported by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on 18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based researchers who signed it in the short time span from 20 September to 6 October 2016

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline